ERAS Fundamental Analysis - ERASCA INC

Fundamental Rating

Taking everything into account, ERAS scores 3 out of 10 in our fundamental rating. ERAS was compared to 560 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ERAS as it has an excellent financial health rating, but there are worries on the profitability. ERAS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ERAS has reported negative net income.

ERAS had a negative operating cash flow in the past year.

In the past 5 years ERAS always reported negative net income.

ERAS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ERAS's Return On Assets of -33.44% is fine compared to the rest of the industry. ERAS outperforms 62.50% of its industry peers.

ERAS has a better Return On Equity (-39.45%) than 70.89% of its industry peers.

		Industry Rank	Sector Rank
ROA	-33.44%
ROE	-39.45%
ROIC	N/A

ROA(3y)-36.99%

ROA(5y)-43.38%

ROE(3y)-45.53%

ROE(5y)-51.63%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ERAS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ERAS has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ERAS has more shares outstanding

There is no outstanding debt for ERAS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 0.75, we must say that ERAS is in the distress zone and has some risk of bankruptcy.

With a decent Altman-Z score value of 0.75, ERAS is doing good in the industry, outperforming 67.86% of the companies in the same industry.

ERAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	0.75

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 12.35 indicates that ERAS has no problem at all paying its short term obligations.

ERAS has a better Current ratio (12.35) than 83.75% of its industry peers.

A Quick Ratio of 12.35 indicates that ERAS has no problem at all paying its short term obligations.

ERAS's Quick ratio of 12.35 is amongst the best of the industry. ERAS outperforms 83.75% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.35
Quick Ratio	12.35

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ERAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.19%, which is quite impressive.

EPS 1Y (TTM)26.19%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%52.17%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.15% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y31.54%

EPS Next 2Y12.98%

EPS Next 3Y10.01%

EPS Next 5Y11.15%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERAS. In the last year negative earnings were reported.

Also next year ERAS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.98%

EPS Next 3Y10.01%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ERAS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ERASCA INC

NASDAQ:ERAS (5/30/2025, 8:00:01 PM)

After market: 1.45 +0.05 (+3.57%)

1.4

-0.05 (-3.45%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-13 2025-05-13/amc

Earnings (Next)08-11 2025-08-11/amc

Inst Owners79.8%

Inst Owner Change-3.87%

Ins Owners7.36%

Ins Owner Change0%

Market Cap396.61M

Analysts85.71

Price Target5.36 (282.86%)

Short Float %9.54%

Short Ratio12.56

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)13.72%

Min EPS beat(2)13.03%

Max EPS beat(2)14.41%

EPS beat(4)3

Avg EPS beat(4)1.81%

Min EPS beat(4)-55.48%

Max EPS beat(4)35.3%

EPS beat(8)6

Avg EPS beat(8)4.05%

EPS beat(12)9

Avg EPS beat(12)-11.88%

EPS beat(16)10

Avg EPS beat(16)-14.99%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)6.52%

PT rev (3m)5%

EPS NQ rev (1m)15.38%

EPS NQ rev (3m)21.43%

EPS NY rev (1m)7.29%

EPS NY rev (3m)14.37%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.99
P/tB	0.99
EV/EBITDA	N/A

EPS(TTM)-0.62

EYN/A

EPS(NY)-0.54

Fwd EYN/A

FCF(TTM)-0.38

FCFYN/A

OCF(TTM)-0.38

OCFYN/A

SpS0

BVpS1.41

TBVpS1.41

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-33.44%
ROE	-39.45%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-36.99%

ROA(5y)-43.38%

ROE(3y)-45.53%

ROE(5y)-51.63%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	2.78%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	12.35
Quick Ratio	12.35
Altman-Z	0.75

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)200.09%

Cap/Depr(5y)425.36%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)26.19%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%52.17%

EPS Next Y31.54%

EPS Next 2Y12.98%

EPS Next 3Y10.01%

EPS Next 5Y11.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-4.06%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year15.15%

EBIT Next 3Y-3.2%

EBIT Next 5YN/A

FCF growth 1Y3.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-3.77%

OCF growth 3YN/A

OCF growth 5YN/A

ERASCA INC (ERAS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens